Aim. To evaluate the influence of combined hypolipidemic therapy (statins in combination with ezetimibe and fenofibrate) and sodium-glucose cotransporter 2 inhibitors on epicardial fat thickness in patients with coronary heart disease and metabolic syndrome. Materials and methods: The study included 49 patients with coronary heart disease and metabolic syndrome who underwent treatment at the Republican Specialized Scientific and Practical Medical Center of Cardiology. The patients were divided into 2 groups: 1) intensive statin therapy in combination with ezetimibe, 2) with the addition of fenofibrate and SGLT2 inhibitors. All patients underwent biochemical tests and imaging marker assessments, followed by comparison of the dynamics within and between groups. Results. When comparing two groups receiving different types of therapy, both groups demonstrated a significant decrease in lipid parameters: LDL-C p<0.001, TC p<0.001, TG p<0.001. Additionally, the group treated with fenofibrate and SGLT2 inhibitors showed a more significant reduction in epicardial fat (11.4 mm in the first group and 10.4 mm in the second group, p<0.05). Conclusion: Pathogenetic therapy with the inclusion of fenofibrate and SGLT2 inhibitors more effectively reduces the level of EFT, as well as TG, VLDL-C, and the TG/HDL index.
| Mualliflar | Kim, Andrey, Shek, Aleksandr, Alieva, Rano, Ким, Андрей, Шек, Александр, Алиева, Рано, Kim, Andrey, Shek, Aleksandr, Aliyeva, Rano |
|---|---|
| Jurnal | O‘zbekiston кardiologiyasi |
| Nashr sanasi | 2025-09-30 |
| Jild | 2 |
| Son | 3 |
| Betlar | 202-211 |
| Til | Rus |
| DOI | 10.70626/cardiouz-2025-2-00052 |
DOI: 10.70626/cardiouz-2025-2-00052 · Maqolaning asl sahifasi
coronary artery disease, epicardial fat thickness, sodium glucose co-transporter 2 inhibitors, metabolic syndrome, fenofibrate, толщина эпикардиального жира, ишемическая болезнь сердца, ингибиторы натрий глюкозного котранспортера 2, метаболический синдром, фенофибрат, Epikardial yog‘ qatlami qalinligi, yurak ishemik kasalligi, natriy-glyukoza kotransporter 2 ingibitorlari, metabolik sindrom, fenofibrat
Aim. To evaluate the immediate clinical and angiographic success in patients with NSTEMI, who underwent percutaneous coronary intervention (PCI) with the installation of a new generation of resorbable scaffolds…
Sudden cardiac death (SCD) in young athletes engaged in regular intensive training represents a rare but highly significant clinical and social problem. Although the incidence is low, SCD typically occurs unexpectedly…
Aim. To assess the prevalence of atherosclerotic lesions of the brachiocephalic arteries (BCA), their association with cardiovascular risk factors, and cardiovascular risk according to the SCORE scale in the population…
In the modern ESH (2023) and ESC (2024) guidelines on arterial hypertension (AH), the following key provisions for the use of combination therapies from the start of treatment have been clearly formulated for the first…
Purpose: to determine the clinical and epidemiological characteristics and laboratory and instrumental research indicators, the profile of cardiovascular risk factors in patients who have suffered myocardial infarction…
Aim. To evaluate the effectiveness of percutaneous coronary intervention (PCI) in patients with ischemic cardiomyopathy and identify opportunities for its improvement, as well as to conduct a comparative analysis with…
Aim. To systematically analyze current approaches to assessing and improving medication adherence in patients after acute myocardial infarction during outpatient follow-up, with a particular focus on factors influencing…
Aim. Systematic analysis and comparison of different reperfusion therapy methods in patients with ST-elevation acute coronary syndrome (STEMI), including primary percutaneous coronary intervention (pPCI) and…
Aim. To assess exercise tolerance and quality of life in patients with chronic heart failure (CHF) and obesity depending on the presence of metabolic syndrome (MS). Materials and methods. The study included patients…
Aim. To evaluate the effectiveness of ulinastatin as part of complex therapy in reducing the incidence of early postoperative complications in patients with multivessel coronary artery disease after CABG. Materials and…